1. Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

3. Management Considerations in mCRC

4. RAS Testing and Use of EGFR Antibody Therapy

5. KRAS and NRAS Mutation Hotspots

6. RAS Mutation Prevalence: Geographic Variation

7. European Society of Pathology Quality Assessment of RAS Laboratory Testing

8. RAS Laboratory Testing: Effect of New Regulations After 1 Year

9. Liquid Biopsy

10. Testing for Circulating Tumor DNA

11. RAS Mutation Testing Using BEAMing PCR

12. Case Discussion: Background

13. Case Discussion: Abdominal CT

14. Case Discussion: Considerations in Assessing Metastatic Disease

15. Considerations for Molecular Testing

16. Considerations for Biopsy Source

17. Considerations for BRAF Testing

18. Case Discussion: First-line Therapy

19. Case Discussion: Second-line Therapy

20. Case Discussion: Considerations After Second-line Therapy

21. Case Discussion: Reassessment Using Liquid Biopsy

22. Potential Applications of Liquid Biopsy

23. Optimizing Use of Liquid Biopsy in Current Clinical Practice

24. Tissue-based vs Liquid Biopsy RAS Analysis: Pros and Cons

25. Mutation Testing: Need for Improved Analysis Time

26. Summary

27. Abbreviations

28. Abbreviations (cont)